Farmacêutica confirms Phase 3 investigation will continue this year, with approval possible before 2025
The American pharmaceutical company Moderna announced at this 4th exhibition (4.04.2023) that the Phase 1/2 trial of a combined influenza and covid-19 vaccine will not be effective as long as they are administered separately.
Second, the vaccine demonstrated strong immune responses against influenza and covid-19 and had a higher safety profile than licensed standalone vaccines.
After two initial phases of testing, the company confirmed it will proceed to Phase 3 in sequence and could review approval of the combination vaccine by 2025.Its purpose is to provide more “Easy and convenient” When it comes to vaccination, this can increase society’s willingness to take the vaccine.
“Combined vaccines offer an important opportunity to improve the experience for consumers and providers, increase compliance with public health recommendations and deliver benefits to health systems.”said Stéphane Bancel, CEO of Moderna.
In a statement, Moderna also provided reports of adverse reactions in groups that participated in both tests and said they were similar to those seen in the group that only received the Covid-19 vaccine.
“Most adverse reactions were grade 1 to 2 in severity. Less than 4% of participants aged 50 years or older reported local or systemic adverse reactions at 3 years. No findings regarding the safety of mRNA-1083 new concerns (called combined vaccine) Compared to an isolated cow,” entrusted to the company.
COVID-19 is not Brazil
The Conass (Conselho Nacional de Secretários de Saúde) reported on the 3rd (3.out) that during the past epidemiological week (24-30.set), 187 deaths due to covid-19 were recorded.
Foram counted 30,956 new cases during the same period. Overall, 705,962 people have died in Brazil since the outbreak began in 2020. Since 2020, the cumulative number of confirmed cases in Brazil is 37,827,912.